Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $132.8 million.

  • Pediatrix Medical's Free Cash Flow rose 4060.89% to $132.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.3 million, marking a year-over-year increase of 11774.73%. This contributed to the annual value of $195.2 million for FY2024, which is 7314.66% up from last year.
  • Pediatrix Medical's Free Cash Flow amounted to $132.8 million in Q3 2025, which was up 4060.89% from $135.0 million recorded in Q2 2025.
  • Pediatrix Medical's 5-year Free Cash Flow high stood at $135.0 million for Q2 2025, and its period low was -$130.6 million during Q1 2024.
  • Moreover, its 5-year median value for Free Cash Flow was $75.8 million (2023), whereas its average is $36.3 million.
  • Over the last 5 years, Pediatrix Medical's Free Cash Flow had its largest YoY gain of 48139.56% in 2021, and its largest YoY loss of 7874.18% in 2021.
  • Quarter analysis of 5 years shows Pediatrix Medical's Free Cash Flow stood at $71.9 million in 2021, then increased by 29.72% to $93.2 million in 2022, then plummeted by 31.4% to $64.0 million in 2023, then skyrocketed by 105.39% to $131.4 million in 2024, then grew by 1.07% to $132.8 million in 2025.
  • Its Free Cash Flow was $132.8 million in Q3 2025, compared to $135.0 million in Q2 2025 and -$120.8 million in Q1 2025.